Avalyn Pharma Inc. Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
Avalyn Pharma Inc. (AVLN) reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations of $211.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations · last filed 2026-08-12
- Avalyn Pharma Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2026-03-31 was $39.99M, a 725.66% increase year-over-year.
- Avalyn Pharma Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2025-03-31 was $4.84M.
| Period end | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 3 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 6 month |
|---|---|---|
| 2026-06-30 | $211.88M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $39.99M 10-Q · filed 2026-06-03 | |
| 2025-06-30 | $37.35M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $4.84M 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |